ggrail

Remaining Grounded Through the Unethical Attacks on Cel Sci

Nice post and right on the mark with regard to the creepy nature of some of the street's more factually dyslexic so called journalists.

CVM was spot on not to respond to the gnats buzzing around its head. They must control their own news cycle. Investors should not worry about the daily price swings in highly charged sectors other than to use as buying opportunities. Let the swing traders swig the Maalox I want to find firms I can believe in and then invest in.

Clarient: New Breast-Cancer Test

Clarient's licensing of the FOXA1 marker appears to be a direct shot across GHDX's bow and may point out some of the fragility of a company that has focused so much of its expenditure and efforts on a single diagnostic regimen with their very good OncotypeDx diagnostic.

The foundations laid by Genomic Health to obtain FDA approval and the costs associated with that Herculean effort paid off initially for them. Now that we are entering a new phase in the maturity of the genomic marker/diagnostics space it may be that the spoils go to the nimble.

The rapid discovery of new markers and the matching of those markers with potential treatment options for cancer and other disease have led to a dizzying palette of choices for pathologists, oncologists and clinicians, not to mention patients.

Clarient's ability to seize the moment and make sound business decisions based on being on being aware of what the latest discoveries have to offer and then most importantly putting their alchemists caps on and creating effective homebrew diagnostics that are applied to the treatment of cancer is an important bridge between treatment and discovery. The ability to absorb and react to change will be the new mantra for success in this space.

Not many companies are so positioned as most of the larger independents have been assimilated by the larger pharmas and biotechs. The future for Clarient will be played out on an ever changing regulatory field so it is not without risk. But the rewards for what CEO Andrews terms as being "technology agnostic" may be great

Clarient, Inc.: Clarifying the Complexities of Cancer

A screaming buy under 2